Healthcare Stocks

ALT and CDX: Why these ASX healthcare stocks were in news today

 ALT and CDX: Why these ASX healthcare stocks were in news today

new devices The S&P/ASX200 ended positively for the third consecutive day of this week, gaining 70.20 points or 0.99%. The index has gained 1.67% over the last five days. The healthcare Index, S&P/ASX 200 Health Care (AXHJ), also ended i...

Read More...
Beamtree (ASX:BMT) signs US$7M contract with Ampath; shares surge 

Beamtree (ASX:BMT) signs US$7M contract with Ampath; shares surge 

  • May 10, 2022 01:23 PM AEST
  • Ritwika

Highlights Beamtree has signed a five-year deal with Ampath for the implementation of its RippleDown software.  The total value of the contract is AU$9.7 million.  Backed by the announcement, the share price of Beamtree has gained mo...

Read More...
From VIP to VRT: Top five dividend-paying stocks from ASX healthcare

From VIP to VRT: Top five dividend-paying stocks from ASX healthcare

Highlights Dividend stocks are a regular flow of income source from investments A dividend is a pay-out of a certain portion of a Company's profit to its investors Stocks paying good dividends give you a stable portfolio Investing in divi...

Read More...
PME, MDR, CSL: A look at three ASX healthcare growth stocks

PME, MDR, CSL: A look at three ASX healthcare growth stocks

Highlights Growth stocks are shares of the company estimated to increase sales and earnings faster than the market These stocks are likely to provide good price appreciation in the future Growth stocks also serve as a good hedge against inflat...

Read More...
3D Printing: A great approach in healthcare innovations

3D Printing: A great approach in healthcare innovations

Highlights 3D printing technology is used in developing new surgical cuttings, patient-specific replicas of bones, organs and blood vessels The innovative technology has created long-lasting and better-fitting implants 3D printers that can rep...

Read More...
Clinuvel (ASX:CUV) shares upbeat results from afamelanotide drug trial

Clinuvel (ASX:CUV) shares upbeat results from afamelanotide drug trial

In a significant development, Clinuvel Pharmaceuticals Ltd (ASX: CUV) received positive results from the clinical study evaluating its drug afamelanotide in arterial ischemic stroke (AIS). The open label final study (CUV 801), the first clinical s...

Read More...
IPD, MX1 & MDR: Three ASX health tech stocks with strong revenue in 3Q

IPD, MX1 & MDR: Three ASX health tech stocks with strong revenue in 3Q

Medical technologies assist healthcare professionals in diagnosing and treating patients with a higher level of accuracy and on time. The next generation of medical technologies holds great potential in advancing the entire health care industry. T...

Read More...
AGN, PYC, KZA: An insight into key highlights of healthcare therapeutics from March quarter

AGN, PYC, KZA: An insight into key highlights of healthcare therapeutics from March quarter

Highlights AGN continued preclinical work targeting the potential use of ARG-007 in other kinds of brain injuries PYC initiated GLP toxicology studies in the RP11 program to support IND submission in 2H 2022 Kazia launched an ATM facility in c...

Read More...
BOD (ASX:BOD) shares gain attention on quarterly update

BOD (ASX:BOD) shares gain attention on quarterly update

  • April 29, 2022 04:15 PM AEST
  • Samta

>   The shares of cannabis-focused drug development and product innovation company Bod Australia Limited (ASX:BOD) are gaining attention following its Q3 FY2022 update. BOD shares traded flat at AU$0.170 per share at 3:36 PM AEST today. ...

Read More...
ResMed (ASX:RMD) revenue takes strong leap in FY22 third quarter

ResMed (ASX:RMD) revenue takes strong leap in FY22 third quarter

  • April 29, 2022 12:18 PM AEST
  • Ritwika

Highlights: ResMed released its unaudited Q3 FY22 results today, stating a 14% gain in revenue.  ResMed’s earnings per share stand at AU$1.22 per share in the given period.  The company will further pay a quarterly dividend wor...

Read More...
Why is Starpharma (ASX:SPL) in news today?

Why is Starpharma (ASX:SPL) in news today?

Highlights: Starpharma is working closely with LloydsPharmacy to bring VIRALEZE back in the UK by this quarter. Starpharma has recorded AU$3.6 million rise in the cash balance within a quarter. The company has reported receipts of AU$9.6 milli...

Read More...

Frequently Asked Questions

Given the fact that healthcare is a necessity, investing in healthcare stocks can be rewarding. However, to make good returns from these stocks, an investor should have sound knowledge about the sector and should be aware of the latest trends in the sector.

The standard checklist that one would run to find a good stock, holds true for screening healthcare stocks too. However, there are few aspects that are important to be considered for healthcare stocks. Well established pharmaceutical stocks with a good history of drug discovery and effective treatments typically have some sort of moat around them, thanks to their scale and financial wherewithal. However, new, and small companies with unique innovations or a strong product pipeline are also worth investigating, as they have a longer runway. Healthcare companies are able to pass on inflation-led input cost pressure, since people usually do not cut back on their healthcare expenses even during an inflationary environment. Companies that are able to maintain good profit margin are seen commanding valuation premiums in the market. Investors can also look for healthcare companies with strong patent portfolio, as patents can provide good price and competition protection for longer periods. Finally, before finalising any share, some of the fundamentals such as return on equity, revenue growth, net margin growth, management capabilities in terms of capital allocation, dividend pay-out should be considered.

Ad

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK